Publisher
Springer Science and Business Media LLC
Reference5 articles.
1. Holmberg D, Mattsson F, Xie S, et al. Risk of gastric and oesophageal adenocarcinoma following discontinuation of long-term proton-pump inhibitor therapy. J Gastroenterol. 2022;57:942–51.
2. Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion. 1986;35(Suppl 1):42–55.
3. Waldum HL, Haugen OA, Isacsen C, et al. Enterochromaffin-like (ECL) tumour cells in the diffuse but not the intestinal type of gastric carcinomas. Eur J Gastroenterol Hepatol. 1991;3:245–9.
4. Haigh CR, Attwood SE, Thompson DG, et al. Gastrin induces proliferation in Barrett’s metaplasia through activation of the CCK2 receptor. Gastroenterology. 2003;124:615–25.
5. Abrams JA, Del Portillo A, Hills C, et al. Randomized controlled trial of the Gastrin/CCK(2) receptor antagonist netazepide in patients with Barrett’s esophagus. Cancer Prev Res (Phila). 2021;14:675–82.